Definium Therapeutics surged ~50% after positive Phase 3 EMERGE data for DT120 in major depressive disorder, demonstrating ...
Zacks Investment Research on MSN
Definium stock soars 50% as phase III depression study meets key goals
Definium Therapeutics DFTX shares surged 49.8% after the company announced positive top-line results from a late-stage study ...
Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results